Sofinnova Announces the Addition of Industry Veteran Sunil Agarwal, MD to its Partnership

Dr. Agarwal has over 16 years of experience in senior executive, scientific and clinical functions. Prior to joining Sofinnova, Sunil was the Executive Vice President and Chief Medical Officer for Ultragenyx, where he built and managed the company's development organization including clinical sciences, clinical operations, regulatory affairs, biometrics, pharmacovigilance, medical affairs, pharmacology and toxicology. At Ultragenyx, he advanced the entire clinical stage pipeline into registration enabling trials and led the company's first breakthrough therapy designation (BTD). Prior to this, Sunil served in various leadership roles at Genentech for over a decade including Senior Vice President of Development for Ophthalmology, Metabolism, Neurology, Immunology and Infectious Diseases. At Genentech he led the global approvals of multiple therapies in both large and orphan indications. Earlier in his career, Sunil was at MedImmune and Guilford Pharmaceuticals, where he served in both development and medical affairs. He currently serves on the Board of Directors for Myokardia and Calithera Biosciences.

Sunil completed his residency at Children's National Medical Center (CNMC), Washington, D.C., and practiced in the CNMC Pediatric Emergency Department. Dr. Agarwal earned his MD from Tufts University School of Medicine and graduated with a BS in Neurobiology from Cornell University. 

"Thoughtful growth of our team is core to our success," says Mike Powell, PhD General Partner. "We are delighted to have Sunil join us. Our portfolio companies will benefit greatly from his development expertise and he will be a key member of the team to identify new investment opportunities," notes Dr. Powell.

"I believe Sofinnova has a terrific track record by always focusing on robust science and therapeutic areas with high unmet medical needs," comments Dr. Agarwal. "I am thrilled to join the Sofinnova family and look forward to contributing to the long-term success of the organization."

Sofinnova recently announced the final closing of its tenth venture fund, raising $650 million in an oversubscribed fund. Sofinnova is managed by experienced venture capitalists and industry executives. The team takes a focused, hands-on approach to company building. 

The partners of SVP X are Jim Healy, MD, PhD, Anand Mehra, MD, Mike Powell, PhD, Sunil Agarwal, MD, Lars Ekman, MD, PhD, David Kabakoff, PhD and Dan Welch.

About Sofinnova

Founded in 1974, Sofinnova specializes in clinical and late preclinical investments in biopharmaceutical products. Our goal is to actively partner with entrepreneurs across all stages of company formation including securing initial funding, building successful management teams, forming impactful corporate alliances, and navigating the M&A acquisition or IPOs' process. We seek to build world class companies that aspire to dramatically improve the current state of medical care today and ultimately, the lives of patients. For more information, please visit www.sofinnova.com

Contact:
Charlotte Shropshire
[email protected]

Photo - http://photos.prnewswire.com/prnh/20161013/428580

Logo - http://photos.prnewswire.com/prnh/20161013/428700LOGO

SOURCE Sofinnova

Related Links

http://www.sofinnova.com